EDIT
Price
$2.40
Change
-$0.09 (-3.61%)
Updated
Oct 23 closing price
Capitalization
368.59M
14 days until earnings call
Intraday BUY SELL Signals
NTLA
Price
$11.21
Change
+$0.05 (+0.45%)
Updated
Oct 23 closing price
Capitalization
1.57B
10 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

EDIT vs NTLA

EDIT vs NTLA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
EDIT vs. NTLA commentary
Oct 26, 2026

Editas Medicine (EDIT) and Intellia Therapeutics (NTLA) are genome research companies in Cambridge, MA founded just after the advent of CRISPR technology in 2012. They develop innovative treatments with gene editing, with a high concentration of Ph.D. and M.D. employees working in multiple collaborations with large pharmaceutical companies that provide additional capital and resources. Fiercely in competition with one another, they seek niches to call their own. NTLA has focused slightly more on blood-related disorders while EDIT has primarily taken aim at cancer and neurological disorders. Both have only reported negative earnings while they strive to bring viable treatments to market. Genome research has been a contentious topic for some time, so political climate is a big variable, and news events cause wild swings in the prices of both. NTLA’s market cap grew significantly in 2021, but it remains to be seen if this will give it a lasting advantage over EDIT.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for EDIT with price predictions
Oct 23, 2026

EDIT in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 14, 2026

EDIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 37 of 43 cases where EDIT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 63 cases where EDIT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.

Following a +9.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 179 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In 78 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 46 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

EDIT moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for EDIT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.501) is normal, around the industry mean (3.035). P/E Ratio (-3.636) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for NTLA with price predictions
Oct 23, 2026

Momentum Indicator for NTLA turns negative, indicating new downward trend

NTLA saw its Momentum Indicator move below the 0 level on October 13, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned negative. In 86 of the 94 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for NTLA turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 44 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

NTLA moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NTLA crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 21 of 21 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTLA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +3.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTLA advanced for three days, in 201 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

The Aroon Indicator entered an Uptrend today. In 100 of 128 cases where NTLA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.159) is normal, around the industry mean (3.035). P/E Ratio (-3.356) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (23.095) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. NTLA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NTLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
EDIT vs NTLA: Fundamental Ratings
EDIT
NTLA
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
48
Fair valued
36
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
7463
P/E GROWTH RATING
1..100
2343
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (36) in the Biotechnology industry is in the same range as EDIT (48). This means that NTLA’s stock grew similarly to EDIT’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EDIT (100). This means that NTLA’s stock grew similarly to EDIT’s over the last 12 months.

NTLA's SMR Rating (98) in the Biotechnology industry is in the same range as EDIT (99). This means that NTLA’s stock grew similarly to EDIT’s over the last 12 months.

NTLA's Price Growth Rating (63) in the Biotechnology industry is in the same range as EDIT (74). This means that NTLA’s stock grew similarly to EDIT’s over the last 12 months.

EDIT's P/E Growth Rating (23) in the Biotechnology industry is in the same range as NTLA (43). This means that EDIT’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITNTLA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
88%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 6 days ago
80%
Bullish Trend 6 days ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 4 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
86%
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
78%
COMPARISON
Comparison
Oct 26, 2026
Stock price -- (EDIT: $2.40 vs. NTLA: $11.21)
Brand notoriety: EDIT and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 43% vs. NTLA: 71%
Market capitalization -- EDIT: $368.59M vs. NTLA: $1.57B
EDIT [@Biotechnology] is valued at $368.59M. NTLA’s [@Biotechnology] market capitalization is $1.57B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $132.8B. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 1 FA rating(s) are green while NTLA’s FA Score has 0 green FA rating(s).

  • EDIT’s FA Score: 1 green, 4 red.
  • NTLA’s FA Score: 0 green, 5 red.
According to our system of comparison, NTLA is a better buy in the long-term than EDIT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 3 TA indicator(s) are bullish while NTLA’s TA Score has 3 bullish TA indicator(s).

  • EDIT’s TA Score: 3 bullish, 5 bearish.
  • NTLA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both EDIT and NTLA are a bad buy in the short-term.

Price Growth

EDIT (@Biotechnology) experienced а +2.13% price change this week, while NTLA (@Biotechnology) price change was -1.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -16.78%.

Reported Earning Dates

EDIT is expected to report earnings on Nov 09, 2026.

NTLA is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (+1.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
EDIT
Daily Signal:
Gain/Loss:
NTLA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PCLO24.89N/A
+0.01%
Virtus SEIX AAA Private Credit CLO ETF
TPIF36.97-0.09
-0.24%
Timothy Plan International ETF (TPIF)
RSPE34.70-0.30
-0.85%
Invesco ESG S&P 500 Equal Weight ETF (RSPE)
SSV.X2.452977-0.027206
-1.10%
ssv.network cryptocurrency
BAT.X0.151236-0.007298
-4.60%
Basic Attention Token cryptocurrency